What is Electromed, Inc.'s earnings per share (EPS)?

Electromed, Inc. (ELMD) reported diluted earnings per share of $1.30 for fiscal year 2026. This represents a 52.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Electromed, Inc. (ELMD) Financials

ELMD

FY2026 annual

Revenue $73.8M +15.3% YoY

Net Income $11.3M +49.9% YoY

EPS (Diluted) $1.30 +52.9% YoY

Free Cash Flow $8.4M -24.4% YoY

Market Cap $229.4M as of Oct 13, 2026

Price / Sales 3.1x on $73.8M revenue, FY2026

Price / Earnings 20.3x on $11.3M net income, FY2026

Price / Book 4.2x on $54.0M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Aug 25, 2026 Currency USD FYE June

Newest figures come from the 10-K for FY2026, filed Aug 25, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ELMD SEC filings page.

Electromed, Inc. (ELMD) reported $73.8M in revenue for fiscal year 2026, up 15.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ELMD FY2026 2026-10-04

Profitability has scaled faster than sales, while cash generation remains positive despite shareholder distributions and rising working-capital needs.

Across FY2022-FY2026, operating margin expanded from 7.1% to 18.8% while revenue grew, showing that expense absorption—not just sales growth—drove the earnings improvement. In FY2026, operating cash flow trailed net income even though free cash flow stayed positive, linking a cash-conversion gap to manageable reinvestment rather than an inability to fund capital spending.

The margin shape points to operating efficiency rather than a dramatic product-economics change: gross margin moved from 75.5% to 78.5%. Operating margin nevertheless reached 18.8%, meaning the larger improvement occurred below gross profit as overhead was absorbed across a larger business.

FY2026’s balance-sheet posture is conservative, with debt-to-equity at 0.2x and current ratio at 4.7x; growth is not being funded by heavy leverage. The company also spent $3.9M on buybacks alongside $1.3M of investing outflow, combining shareholder distributions with continued reinvestment.

Financial Health Signals

Financial Health Score 79/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Electromed, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Electromed, Inc. has an operating margin of 18.8%, meaning the company retains $19 of operating profit per $100 of revenue. This strong profitability earns a score of 75/100, reflecting efficient cost management and pricing power. This is up from 15.1% the prior year.

Growth

Electromed, Inc.'s revenue surged 15.3% year-over-year to $73.8M, reflecting rapid business expansion. This strong growth earns a score of 78/100.

Leverage

Electromed, Inc. carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 73/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.69, Electromed, Inc. holds $4.69 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 91/100.

Cash Flow

Electromed, Inc. converts 11.4% of revenue into free cash flow ($8.4M). This strong cash generation earns a score of 76/100.

Returns

Electromed, Inc. earns a strong 20.9% return on equity (ROE), meaning it generates $21 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 82/100. This is up from 17.4% the prior year.

Altman Z-Score Safe

14.43

Electromed, Inc. scores 14.43, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($229.4M) relative to total liabilities ($12.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

Electromed, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

0.86x

For every $1 of reported earnings, Electromed, Inc. generates $0.86 in operating cash flow ($9.7M OCF vs $11.3M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$19.4M

YoY+11.6%

QoQ+4.5%

5Y CAGR+15.4%

10Y CAGR+13.1%

Electromed, Inc. generated $19.4M in revenue in Q4 2026. This represents an increase of 11.6% from the same quarter a year earlier. Against the prior quarter it is up 4.5%.

EBITDA

$3.9M

YoY+14.8%

QoQ-2.6%

5Y CAGR+37.5%

10Y CAGR+18.4%

Electromed, Inc.'s EBITDA was $3.9M in Q4 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.8% from the same quarter a year earlier. Against the prior quarter it is down 2.6%.

Net Income

$3.4M

YoY+54.3%

QoQ+13.3%

5Y CAGR+53.5%

10Y CAGR+26.0%

Electromed, Inc. reported $3.4M in net income in Q4 2026. This represents an increase of 54.3% from the same quarter a year earlier. Against the prior quarter it is up 13.3%.

EPS (Diluted)

$0.39

YoY+50.0%

QoQ+11.4%

5Y CAGR+50.8%

10Y CAGR+25.6%

Electromed, Inc. earned $0.39 per diluted share (EPS) in Q4 2026. This represents an increase of 50.0% from the same quarter a year earlier. Against the prior quarter it is up 11.4%.

Cash & Balance Sheet

Free Cash Flow

$2.8M

YoY-25.3%

QoQ-16.6%

5Y CAGR+37.2%

10Y CAGR+28.9%

Electromed, Inc. generated $2.8M in free cash flow in Q4 2026, representing cash available after capex. This represents a decrease of 25.3% from the same quarter a year earlier. Against the prior quarter it is down 16.6%.

Cash & Debt

$20.4M

YoY+33.8%

QoQ+20.4%

5Y CAGR+11.5%

10Y CAGR+14.8%

Electromed, Inc. held $20.4M in cash as of Q4 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+0.2%

QoQ+1.0%

5Y CAGR-0.5%

10Y CAGR+0.2%

Electromed, Inc. had 8M shares outstanding in Q4 2026. This represents an increase of 0.2% from the same quarter a year earlier. Against the prior quarter it is up 1.0%.

Dividends Per Share

Not reported for Q4 2026.

Margins & Returns

Gross Margin

78.7%

YoY+0.4pp

QoQ-0.1pp

5Y change+5.5pp

10Y change-0.2pp

Electromed, Inc.'s gross margin was 78.7% in Q4 2026, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.

Operating Margin

19.7%

YoY+2.2pp

QoQ-0.6pp

5Y change+12.8pp

10Y change+10.2pp

Electromed, Inc.'s operating margin was 19.7% in Q4 2026, reflecting core business profitability. This is up 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.

Net Margin

17.5%

YoY+4.8pp

QoQ+1.3pp

5Y change+13.3pp

10Y change+11.6pp

Electromed, Inc.'s net profit margin was 17.5% in Q4 2026, showing the share of revenue converted to profit. This is up 4.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.

Return on Equity

6.3%

YoY+1.2pp

QoQ+0.2pp

5Y change+5.1pp

10Y change+4.2pp

Electromed, Inc.'s ROE was 6.3% in Q4 2026, measuring profit generated per dollar of shareholder equity. This is up 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Capital Allocation

R&D Spending

$328K

YoY+8.6%

QoQ-9.1%

5Y CAGR+0.1%

10Y CAGR+5.2%

Electromed, Inc. invested $328K in research and development in Q4 2026. This represents an increase of 8.6% from the same quarter a year earlier. Against the prior quarter it is down 9.1%.

Share Buybacks

YoY-100.0%

QoQ-100.0%

Electromed, Inc. repurchased no shares in Q4 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Capital Expenditures

$219K

YoY+51.0%

QoQ+49.0%

5Y CAGR+3.8%

10Y CAGR-2.4%

Electromed, Inc. invested $219K in capex in Q4 2026, funding long-term assets and infrastructure. This represents an increase of 51.0% from the same quarter a year earlier. Against the prior quarter it is up 49.0%.

ELMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ELMD quarterly income statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$73.8M+15.3%	$64.0M+17.0%	$54.7M+13.8%	$48.1M+15.4%	$41.7M+16.5%	$35.8M+10.1%	$32.5M+3.7%	$31.3M+10.6%	$28.3M+9.5%	$25.9M+12.5%	$23.0M+18.5%	$19.4M+25.3%	$15.5M+2.5%	$15.1M-22.6%	$19.5M
Cost of Revenue	$15.8M+12.9%	$14.0M+8.0%	$13.0M+12.5%	$11.5M+13.0%	$10.2M+20.9%	$8.5M+16.2%	$7.3M-2.4%	$7.5M+14.0%	$6.5M+23.5%	$5.3M+3.5%	$5.1M-11.9%	$5.8M+19.7%	$4.9M+4.3%	$4.7M-13.5%	$5.4M
Gross Profit	$57.9M+16.0%	$50.0M+19.8%	$41.7M+14.3%	$36.5M+16.1%	$31.4M+15.2%	$27.3M+8.4%	$25.2M+5.7%	$23.8M+9.5%	$21.8M+5.9%	$20.6M+15.1%	$17.9M+31.4%	$13.6M+27.9%	$10.6M+1.8%	$10.4M-26.1%	$14.1M
R&D Expenses	$1.3M+31.9%	$996K+51.8%	$656K-28.4%	$916K-32.4%	$1.4M-21.3%	$1.7M+64.0%	$1.1M+80.0%	$583K+132.0%	$251K-57.9%	$597K+56.9%	$380K+20.5%	$316K-32.3%	$466K-22.8%	$603K-34.5%	$921K
SG&A Expenses	$42.7M+8.7%	$39.3M+14.0%	$34.5M+9.2%	$31.6M+16.5%	$27.1M+20.8%	$22.4M+12.5%	$19.9M-2.4%	$20.4M+8.6%	$18.8M+14.7%	$16.4M+14.0%	$14.4M+20.1%	$12.0M+9.8%	$10.9M-6.5%	$11.7M-7.5%	$12.6M
Operating Income	$13.9M+43.7%	$9.7M+46.8%	$6.6M+64.2%	$4.0M+34.9%	$3.0M-5.4%	$3.1M-38.6%	$5.1M+80.9%	$2.8M+4.3%	$2.7M-24.0%	$3.6M+14.8%	$3.1M+137.3%	$1.3M+276.9%	-$741K+59.5%	-$1.8M-401.4%	$606K
EBITDA	$14.8M+36.7%	$10.8M+45.9%	$7.4M+60.6%	$4.6M+28.4%	$3.6M-4.0%	$3.8M-36.0%	$5.9M+56.0%	$3.8M+7.2%	$3.5M-19.0%	$4.3M+12.4%	$3.8M+88.0%	$2.0M+4642.9%	-$45K+96.4%	-$1.2M-208.7%	$1.1M
Interest Expense	N/A	N/A	$455K+483.3%	$78K+212.0%	$25K-7.4%	$27K-77.7%	$121K+33.4%	$91K+356.5%	$20K+139.8%	-$50K+25.4%	-$67K-177.9%	$86K+8.5%	$79K-32.4%	$117K-30.7%	$169K
Income Tax	$3.1M+11.4%	$2.7M+45.7%	$1.9M+105.0%	$920K+32.9%	$692K-14.0%	$805K-25.3%	$1.1M+14.7%	$940K+4.3%	$901K-30.2%	$1.3M+55.4%	$830K+528.8%	$132K-71.9%	$469K+176.3%	-$615K-345.0%	$251K
Net Income	$11.3M+49.9%	$7.5M+46.3%	$5.2M+62.7%	$3.2M+37.4%	$2.3M-2.4%	$2.4M-43.2%	$4.2M+110.1%	$2.0M+8.1%	$1.8M-17.9%	$2.2M+0.8%	$2.2M+102.5%	$1.1M+184.8%	-$1.3M+3.1%	-$1.3M-812.3%	$187K
EPS (Basic)	$1.37+53.9%	$0.89+48.3%	$0.60+62.2%	$0.37+37.0%	$0.27-3.6%	$0.28-44.0%	$0.50+108.3%	$0.24+9.1%	$0.22-18.5%	$0.270.0%	$0.27+107.7%	$0.13+181.3%	-$0.16	N/A	$0.02
EPS (Diluted)	$1.30+52.9%	$0.85+46.6%	$0.58+61.1%	$0.36+38.5%	$0.26-3.7%	$0.27-42.6%	$0.47+104.3%	$0.23+9.5%	$0.21-19.2%	$0.26-3.7%	$0.27+107.7%	$0.13+181.3%	-$0.16	N/A	$0.02
Diluted Shares (Avg)	9M-2.5%	9M+0.6%	9M+1.9%	9M-0.8%	9M-1.6%	9M+1.0%	9M+2.3%	9M+0.1%	9M+1.9%	8M+2.6%	8M+1.2%	8M+0.5%	8M0.0%	8M0.0%	8M

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Revenue	$19.4M+11.6%	$18.6M+18.4%	$18.9M+16.3%	$16.9M+15.1%	$17.4M+17.3%	$15.7M+13.1%	$16.3M+18.7%	$14.7M+19.0%
Cost of Revenue	$4.1M+9.7%	$3.9M+13.8%	$4.1M+12.4%	$3.7M+16.1%	$3.8M+6.7%	$3.5M-1.0%	$3.6M+15.4%	$3.2M+12.4%
Gross Profit	$15.3M+12.2%	$14.6M+19.7%	$14.8M+17.4%	$13.2M+14.8%	$13.6M+20.6%	$12.2M+17.8%	$12.6M+19.7%	$11.5M+21.0%
R&D Expenses	$328K+8.6%	$361K+30.3%	$384K+53.0%	$241K+45.2%	$302K+71.6%	$277K+65.9%	$251K+134.6%	$166K-19.4%
SG&A Expenses	$11.1M+8.3%	$10.5M+7.2%	$10.8M+10.0%	$10.3M+9.6%	$10.3M+17.0%	$9.8M+17.2%	$9.8M+20.3%	$9.4M+2.6%
Operating Income	$3.8M+25.8%	$3.8M+76.0%	$3.6M+42.4%	$2.7M+37.8%	$3.0M+30.2%	$2.1M+16.2%	$2.5M+12.3%	$1.9M+1264.8%
EBITDA	$3.9M+14.8%	$4.1M+67.3%	$3.9M+37.8%	$2.9M+35.7%	$3.4M+35.0%	$2.4M+18.3%	$2.8M+13.8%	$2.2M+506.2%
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$152K+58.3%	$195K+153.2%
Income Tax	$560K-42.3%	$863K+120.7%	$968K+33.3%	$668K+1.4%	$971K+45.1%	$391K-16.5%	$726K+6.0%	$659K+929.7%
Net Income	$3.4M+54.3%	$3.0M+58.8%	$2.8M+40.3%	$2.1M+44.9%	$2.2M+20.6%	$1.9M+26.7%	$2.0M+17.6%	$1.5M+851.0%
EPS (Basic)	$0.41+57.7%	$0.37+68.2%	$0.33+43.5%	$0.26+52.9%	$0.26+23.8%	$0.22+29.4%	$0.23+15.0%	$0.17+750.0%
EPS (Diluted)	$0.39+50.0%	$0.35+66.7%	$0.32+45.5%	$0.25+56.3%	$0.26+30.0%	$0.21+23.5%	$0.22+15.8%	$0.16+700.0%
Diluted Shares (Avg)	N/A	9M-3.6%	9M-2.9%	9M-3.3%	N/A	9M+0.8%	9M+1.7%	9M+2.3%

ELMD Balance Sheet

ELMD quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$66.3M+23.2%	$53.8M+3.0%	$52.2M+14.0%	$45.8M+10.7%	$41.4M+11.5%	$37.1M+11.6%	$33.2M+13.1%	$29.4M+7.3%	$27.4M+18.8%	$23.1M+12.1%	$20.6M+18.2%	$17.4M+10.2%	$15.8M-10.0%	$17.6M-16.1%	$20.9M
Current Assets	$57.4M+27.3%	$45.1M+2.1%	$44.2M+16.9%	$37.8M+9.4%	$34.5M+8.9%	$31.7M+13.1%	$28.0M+14.2%	$24.5M+5.4%	$23.3M+26.0%	$18.5M+16.7%	$15.8M+25.7%	$12.6M+18.5%	$10.6M-14.5%	$12.4M-23.8%	$16.3M
Cash & Equivalents	$20.4M+33.8%	$15.3M-4.9%	$16.1M+118.1%	$7.4M-9.6%	$8.2M-31.4%	$11.9M+13.5%	$10.5M+34.2%	$7.8M+4.7%	$7.5M+33.8%	$5.6M+8.8%	$5.1M+42.4%	$3.6M+139.5%	$1.5M+198.4%	$504K-70.4%	$1.7M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.7M+11.6%	$3.3M-11.1%	$3.7M-12.1%	$4.2M+32.8%	$3.2M+50.3%	$2.1M-31.5%	$3.1M+17.7%	$2.6M+5.4%	$2.5M-2.8%	$2.6M+3.2%	$2.5M+19.7%	$2.1M-7.3%	$2.2M+62.0%	$1.4M-42.3%	$2.4M
Accounts Receivable	$29.8M+20.9%	$24.7M+5.7%	$23.3M-3.3%	$24.1M+14.6%	$21.1M+23.6%	$17.0M+31.6%	$12.9M+1.4%	$12.8M+8.0%	$11.8M+18.7%	$9.9M+30.7%	$7.6M+16.8%	$6.5M+0.5%	$6.5M-28.0%	$9.0M-16.9%	$10.9M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$12.3M+16.0%	$10.6M+37.8%	$7.7M-5.5%	$8.1M+13.2%	$7.2M+53.2%	$4.7M+56.7%	$3.0M-18.3%	$3.7M-22.7%	$4.7M+18.8%	$4.0M-5.4%	$4.2M+21.2%	$3.5M+13.3%	$3.1M-15.4%	$3.6M-37.9%	$5.8M
Current Liabilities	$12.2M+16.8%	$10.5M+36.4%	$7.7M-4.7%	$8.1M+12.6%	$7.2M+54.1%	$4.6M+55.4%	$3.0M-18.2%	$3.7M-24.0%	$4.8M+65.9%	$2.9M-5.7%	$3.1M+34.8%	$2.3M+25.2%	$1.8M-17.0%	$2.2M-47.4%	$4.2M
Non-Current Liabilities	$66K-47.2%	$125K+941.7%	$12K-86.0%	$86K+109.8%	$41K-24.1%	$54K+500.0%	$9K-38.9%	$15K+124.5%	-$60K-105.5%	$1.1M-4.3%	$1.1M-4.7%	$1.2M-3.9%	$1.3M-12.8%	$1.4M-14.0%	$1.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.1M-4.3%	$1.1M-4.7%	$1.2M-3.9%	$1.3M-6.1%	$1.3M-4.1%	$1.4M
Total Equity	$54.0M+24.9%	$43.2M-3.0%	$44.5M+18.3%	$37.7M+10.2%	$34.2M+5.4%	$32.4M+7.2%	$30.3M+17.5%	$25.7M+14.0%	$22.6M+13.8%	$19.8M+21.2%	$16.4M+17.5%	$13.9M+9.5%	$12.7M-8.7%	$13.9M-7.6%	$15.1M
Retained Earnings	$28.6M+34.8%	$21.2M-10.5%	$23.7M+25.9%	$18.8M+19.1%	$15.8M+5.7%	$14.9M+9.0%	$13.7M+43.7%	$9.5M0.0%	$9.5M+92.1%	$5.0M+81.8%	$2.7M+429.9%	$515K+189.1%	-$578K-181.3%	$711K-65.2%	$2.0M

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Total Assets	$66.3M+23.2%	$59.5M+13.4%	$54.9M+5.0%	$53.6M+9.6%	$53.8M+3.0%	$52.5M+7.3%	$52.3M+11.3%	$48.9M+11.0%
Current Assets	$57.4M+27.3%	$50.2M+13.7%	$45.6M+3.1%	$44.6M+8.7%	$45.1M+2.1%	$44.2M+7.0%	$44.2M+12.5%	$41.0M+13.3%
Cash & Equivalents	$20.4M+33.8%	$17.0M+11.5%	$13.8M-15.1%	$14.1M+1.8%	$15.3M-4.9%	$15.2M+30.1%	$16.2M+55.6%	$13.9M+97.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.7M+11.6%	$3.3M+11.0%	$3.5M+12.2%	$3.8M+9.8%	$3.3M-11.1%	$3.0M-29.0%	$3.1M-35.3%	$3.4M-23.3%
Accounts Receivable	$29.8M+20.9%	$28.3M+20.5%	$26.3M+15.3%	$24.8M+10.7%	$24.7M+5.7%	$23.4M-1.9%	$22.8M-0.9%	$22.4M-4.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$12.3M+16.0%	$10.3M+21.1%	$9.5M+9.2%	$8.9M+19.4%	$10.6M+37.8%	$8.5M+33.9%	$8.7M+30.9%	$7.4M+27.1%
Current Liabilities	$12.2M+16.8%	$10.2M+20.2%	$9.4M+8.2%	$8.8M+18.1%	$10.5M+36.4%	$8.5M+34.5%	$8.7M+31.9%	$7.4M+28.4%
Non-Current Liabilities	$66K-47.2%	$81K	$96K+2300.0%	$110K+1275.0%	$125K+941.7%	$0-100.0%	$4K-91.8%	$8K-88.2%
Total Equity	$54.0M+24.9%	$49.2M+11.9%	$45.4M+4.2%	$44.7M+7.9%	$43.2M-3.0%	$43.9M+3.3%	$43.6M+8.1%	$41.5M+8.5%
Retained Earnings	$28.6M+34.8%	$25.1M+11.4%	$22.3M-1.3%	$22.3M+8.4%	$21.2M-10.5%	$22.6M+2.0%	$22.6M+9.5%	$20.6M+8.6%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

ELMD Cash Flow Statement

ELMD quarterly cash flow statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$9.7M-15.2%	$11.4M+25.7%	$9.1M+589.5%	$1.3M+291.7%	-$686K-122.3%	$3.1M-26.7%	$4.2M+62.0%	$2.6M+6.0%	$2.4M+105.0%	$1.2M-45.0%	$2.2M-22.1%	$2.8M+34.5%	$2.1M+10.2%	$1.9M+260.2%	-$1.2M
Depreciation & Amortization	$926K-21.0%	$1.2M+39.4%	$841K+37.2%	$613K-2.4%	$628K+3.0%	$610K-17.7%	$741K-19.9%	$925K+17.1%	$790K+4.6%	$755K+2.2%	$739K+0.3%	$736K+5.8%	$696K+17.9%	$590K+10.7%	$533K
Stock-Based Compensation	$2.7M-11.0%	$3.1M+80.8%	$1.7M+139.0%	$708K-27.5%	$976K-4.7%	$1.0M+13.5%	$902K-2.4%	$924K+7.1%	$863K+79.9%	$479K+115.2%	$223K+101.9%	$110K+34.2%	$82K-53.2%	$176K+29.6%	$136K
Capital Expenditures	$1.3M+377.9%	$262K-8.7%	$287K-82.6%	$1.6M+15.6%	$1.4M+396.5%	$287K-66.0%	$844K-36.6%	$1.3M+152.9%	$526K-15.0%	$619K+15.7%	$535K+2.2%	$523K-41.6%	$895K-11.9%	$1.0M+28.4%	$792K
Free Cash Flow	$8.4M-24.4%	$11.1M+26.8%	$8.8M+2736.6%	-$333K+84.2%	-$2.1M-175.7%	$2.8M-16.8%	$3.4M+166.2%	$1.3M-34.3%	$1.9M+234.8%	$572K-64.9%	$1.6M-27.7%	$2.3M+92.7%	$1.2M+36.3%	$860K+143.8%	-$2.0M
Investing Cash Flow	-$1.3M-324.8%	-$306K+22.5%	-$395K+77.0%	-$1.7M-12.5%	-$1.5M-240.4%	-$448K+54.1%	-$977K+29.5%	-$1.4M-142.5%	-$572K+16.8%	-$687K-18.6%	-$580K	N/A	N/A	N/A	-$849K
Financing Cash Flow	-$3.2M+73.0%	-$11.9M-33100.0%	$36K+109.5%	-$380K+75.1%	-$1.5M-25.1%	-$1.2M-122.4%	-$548K+35.6%	-$851K-7367.3%	$12K+121.8%	-$54K+13.9%	-$62K-1.8%	-$61K	N/A	N/A	-$369K
Share Buybacks	$3.9M-60.8%	$10.0M+3536.4%	$275K+79.7%	$153K-89.4%	$1.4M+28.8%	$1.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Operating Cash Flow	$3.0M-22.4%	$3.5M+67.6%	$3.0M-4.0%	$169K-92.7%	$3.9M-14.0%	$2.1M+53.5%	$3.2M-9.2%	$2.3M+1046.3%
Depreciation & Amortization	$122K-69.3%	$287K+1.4%	$258K-5.1%	$259K+17.7%	$397K+89.0%	$283K+36.1%	$272K+30.1%	$220K+2.8%
Stock-Based Compensation	N/A	N/A	N/A	$458K-34.3%	N/A	N/A	N/A	$697K+87.9%
Capital Expenditures	$219K+51.0%	$147K-3.9%	$634K+172.1%	$252K+581.1%	$145K+559.1%	-$153K+80.0%	$233K+228.2%	$37K-66.1%
Free Cash Flow	$2.8M-25.3%	$3.3M+73.3%	$2.4M-18.0%	-$83K-103.7%	$3.7M-16.9%	$1.9M+51.7%	$2.9M-14.2%	$2.3M+743.6%
Investing Cash Flow	-$223K-42.0%	-$154K-205.5%	-$656K-176.8%	-$267K-360.3%	-$157K-241.3%	$146K+213.2%	-$237K-172.4%	-$58K+56.4%
Financing Cash Flow	$694K+119.0%	-$128K+96.0%	-$2.7M-395.8%	-$1.1M+75.9%	-$3.7M-4769.3%	-$3.2M-5846.4%	-$543K-2188.5%	-$4.5M-15503.4%
Share Buybacks	$0-100.0%	$152K-91.5%	$2.8M	$1.0M-77.9%	$3.7M+1234.2%	$1.8M	$0	$4.5M

Not reported in any period shown, so not listed: Dividends Paid.

ELMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ELMD quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	78.5%+0.5pp	78.1%+1.8pp	76.3%+0.3pp	76.0%+0.5pp	75.5%-0.9pp	76.4%-1.3pp	77.6%+1.4pp	76.2%-0.7pp	76.9%-2.6pp	79.5%+1.8pp	77.8%+7.7pp	70.1%+1.4pp	68.7%-0.5pp	69.2%-3.3pp	72.5%
Operating Margin	18.8%+3.7pp	15.1%+3.1pp	12.0%+3.7pp	8.3%+1.2pp	7.1%-1.7pp	8.8%-7.0pp	15.8%+6.7pp	9.0%-0.5pp	9.6%-4.2pp	13.8%+0.3pp	13.5%+6.8pp	6.8%+11.5pp	-4.8%+7.3pp	-12.1%-15.2pp	3.1%
Net Margin	15.3%+3.5pp	11.8%+2.4pp	9.4%+2.8pp	6.6%+1.1pp	5.5%-1.1pp	6.6%-6.2pp	12.8%+6.5pp	6.3%-0.1pp	6.5%-2.2pp	8.6%-1.0pp	9.6%+4.0pp	5.6%+14.0pp	-8.3%+0.5pp	-8.8%-9.8pp	1.0%
Return on Equity	20.9%+3.5pp	17.4%+5.9pp	11.6%+3.1pp	8.4%+1.7pp	6.8%-0.5pp	7.3%-6.5pp	13.8%+6.1pp	7.7%-0.4pp	8.1%-3.1pp	11.2%-2.3pp	13.5%+5.7pp	7.8%+18.0pp	-10.1%-0.6pp	-9.5%-10.8pp	1.2%
Return on Assets	17.1%+3.0pp	14.0%+4.2pp	9.9%+2.9pp	6.9%+1.3pp	5.6%-0.8pp	6.4%-6.2pp	12.5%+5.8pp	6.7%+0.1pp	6.7%-3.0pp	9.7%-1.1pp	10.8%+4.5pp	6.3%+14.4pp	-8.2%-0.6pp	-7.6%-8.5pp	0.9%
Current Ratio	4.69+0.4x	4.31-1.4x	5.75+1.1x	4.69-0.1x	4.83-2.0x	6.83-2.6x	9.38+2.7x	6.72+1.9x	4.85-1.5x	6.38+1.2x	5.15-0.4x	5.52-0.3x	5.84+0.2x	5.66+1.8x	3.91
Debt-to-Equity	0.230.0x	0.25+0.1x	0.170.0x	0.220.0x	0.21+0.1x	0.140.0x	0.100.0x	0.14-0.1x	0.21+0.2x	0.060.0x	0.070.0x	0.090.0x	0.100.0x	0.100.0x	0.09
Asset Turnover	1.11-0.1x	1.19+0.1x	1.050.0x	1.050.0x	1.010.0x	0.960.0x	0.98-0.1x	1.060.0x	1.03-0.1x	1.120.0x	1.120.0x	1.12+0.1x	0.98+0.1x	0.86-0.1x	0.93
FCF Margin	11.4%-6.0pp	17.4%+1.3pp	16.1%+16.7pp	-0.7%+4.4pp	-5.1%-12.9pp	7.8%-2.5pp	10.3%+6.3pp	4.0%-2.7pp	6.8%+4.6pp	2.2%-4.9pp	7.1%-4.5pp	11.6%+4.1pp	7.6%+1.9pp	5.7%+15.8pp	-10.1%

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Gross Margin	78.7%+0.4pp	78.8%+0.9pp	78.4%+0.7pp	78.1%-0.2pp	78.3%+2.1pp	78.0%+3.1pp	77.7%+0.7pp	78.3%+1.3pp
Operating Margin	19.7%+2.2pp	20.3%+6.6pp	19.2%+3.5pp	15.8%+2.6pp	17.5%+1.7pp	13.6%+0.4pp	15.6%-0.9pp	13.2%+12.1pp
Net Margin	17.5%+4.8pp	16.2%+4.1pp	14.6%+2.5pp	12.7%+2.6pp	12.7%+0.4pp	12.1%+1.3pp	12.1%-0.1pp	10.1%+8.8pp
Return on Equity	6.3%+1.2pp	6.1%+1.8pp	6.1%+1.6pp	4.8%+1.2pp	5.1%+1.0pp	4.3%+0.8pp	4.5%+0.4pp	3.5%+3.1pp
Return on Assets	5.1%+1.0pp	5.1%+1.4pp	5.0%+1.3pp	4.0%+1.0pp	4.1%+0.6pp	3.6%+0.6pp	3.8%+0.2pp	3.0%+2.7pp
Current Ratio	4.69+0.4x	4.91-0.3x	4.86-0.2x	5.09-0.4x	4.31-1.4x	5.19-1.3x	5.10-0.9x	5.53-0.7x
Debt-to-Equity	0.230.0x	0.210.0x	0.210.0x	0.200.0x	0.25+0.1x	0.190.0x	0.200.0x	0.180.0x
Asset Turnover	0.290.0x	0.310.0x	0.340.0x	0.320.0x	0.320.0x	0.300.0x	0.310.0x	0.300.0x
FCF Margin	14.3%-7.1pp	17.9%+5.7pp	12.7%-5.3pp	-0.5%-16.0pp	21.3%-8.8pp	12.3%+3.1pp	17.9%-6.9pp	15.5%+18.4pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Electromed, Inc. ELMD	FY2026	$73.8M	$11.3M	15.3%	$229.4M	79/100
Inogen Inc INGN	FY2025	$348.7M	$22.7M	6.5%	$164.0M	42/100
Neuronetics, Inc. STIM	FY2025	$149.2M	-$39.0M	-26.2%	$162.3M	42/100
CVRx, Inc. CVRX	FY2025	$56.7M	-$53.3M	-94.1%	$42.1M	50/100
BioSig Technologies, Inc. BSGM	FY2025	N/A	-$462.8M	N/A	$157.0M	—
Sight Sciences, Inc. SGHT	FY2025	$77.4M	-$38.4M	-49.7%	$489.7M	57/100

Where Electromed, Inc. Ranks

Frequently Asked Questions

What is Electromed, Inc.'s annual revenue?

Electromed, Inc. (ELMD) reported $73.8M in total revenue for fiscal year 2026. This represents a 15.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Electromed, Inc.'s revenue growing?

Electromed, Inc. (ELMD) revenue grew by 15.3% year-over-year, from $64.0M to $73.8M in fiscal year 2026.

Is Electromed, Inc. profitable?

Yes, Electromed, Inc. (ELMD) reported a net income of $11.3M in fiscal year 2026, with a net profit margin of 15.3%.

What is Electromed, Inc.'s EBITDA?

Electromed, Inc. (ELMD) had EBITDA of $14.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Electromed, Inc.'s gross margin?

Electromed, Inc. (ELMD) had a gross margin of 78.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Electromed, Inc.'s operating margin?

Electromed, Inc. (ELMD) had an operating margin of 18.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Electromed, Inc.'s net profit margin?

Electromed, Inc. (ELMD) had a net profit margin of 15.3% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Electromed, Inc.'s return on equity (ROE)?

Electromed, Inc. (ELMD) has a return on equity of 20.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Electromed, Inc.'s free cash flow?

Electromed, Inc. (ELMD) generated $8.4M in free cash flow during fiscal year 2026. This represents a -24.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Electromed, Inc.'s operating cash flow?

Electromed, Inc. (ELMD) generated $9.7M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Electromed, Inc.'s total assets?

Electromed, Inc. (ELMD) had $66.3M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Electromed, Inc.'s capital expenditures?

Electromed, Inc. (ELMD) invested $1.3M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Electromed, Inc. spend on research and development?

Electromed, Inc. (ELMD) invested $1.3M in research and development during fiscal year 2026.

Does Electromed, Inc. buy back shares?

Yes, Electromed, Inc. (ELMD) spent $3.9M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Electromed, Inc. have outstanding?

Electromed, Inc. (ELMD) had 8M shares outstanding as of fiscal year 2026.

What is Electromed, Inc.'s current ratio?

Electromed, Inc. (ELMD) had a current ratio of 4.69 as of fiscal year 2026, which is generally considered healthy.

What is Electromed, Inc.'s debt-to-equity ratio?

Electromed, Inc. (ELMD) had a debt-to-equity ratio of 0.23 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Electromed, Inc.'s return on assets (ROA)?

Electromed, Inc. (ELMD) had a return on assets of 17.1% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Electromed, Inc.'s P/E ratio?

Electromed, Inc. (ELMD) trades at 20.3x earnings, its market capitalization divided by net income of $11.3M net income, FY2026. The market capitalization is $229.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Electromed, Inc.'s price-to-sales ratio?

Electromed, Inc. (ELMD) trades at 3.1x sales, its market capitalization divided by revenue of $73.8M revenue, FY2026. The market capitalization is $229.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Electromed, Inc.'s Altman Z-Score?

Electromed, Inc. (ELMD) has an Altman Z-Score of 14.43, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Electromed, Inc.'s Piotroski F-Score?

Electromed, Inc. (ELMD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Electromed, Inc.'s earnings high quality?

Electromed, Inc. (ELMD) has an earnings quality ratio of 0.86x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Electromed, Inc.?

Electromed, Inc. (ELMD) scores 79 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.